Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1741 to 1750 of 2575 total matches.

In Brief: Erenumab (Aimovig) Hypersensitivity

   
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019  (Issue 1568)
of erenumabaooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP ...
The FDA has approved changes to the labeling of erenumab-aooe (Aimovig)1, a once-monthly, subcutaneously injected calcitonin gene-related peptide (CGRP) blocker approved in 2018 for prevention of migraine. The new label contains a warning about hypersensitivity reactions, including rash, angioedema, and anaphylaxis, that have been reported with post-marketing use of the drug.According to the label, most of these reactions were not serious and occurred within hours after receiving the drug, but some occurred more than one week after administration. Because these reactions are voluntarily...
Med Lett Drugs Ther. 2019 Mar 25;61(1568):48 |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
tonic-clonic” (see Table 1). The new terminology is used here. Controlled monotherapy trials ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Drugs for Assisted Reproduction

   
Treatment Guidelines from The Medical Letter • Oct 01, 2003  (Issue 14)
. (ISSN 1541-2784) Vol. 1 (Issue 14) October 2003 Published by The Medical Letter, Inc. 1000 Main ...
Infertility occurs in about 15% of couples. About one third of infertility is due to problems with ovulation or an anatomic abnormality of the fallopian tube or peritoneum, such as scarring, adhesions or endometriosis. Another third is due to a male infertility factor, most commonly insufficient sperm production or abnormal motility or morphology. The remaining third is unexplained. In older women unexplained infertility is probably caused by diminished quality and quantity of oocytes, decreased implantation and spontaneous pregnancy wastage.
Treat Guidel Med Lett. 2003 Oct;1(14):89-92 |  Show IntroductionHide Introduction

In Brief: A Naloxone Auto-Injector (Evzio)

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014  (Issue 1444)
from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency ...
A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency treatment of life-threatening opioid overdose in adults and children: a single-dose naloxone auto-injector (Evzio – Kaleo) for intramuscular or subcutaneous use.Evzio will be available in kits containing two prefilled 0.4-mg auto-injectors with voice guidance and a "trainer" device that also has voice guidance, but does not...
Med Lett Drugs Ther. 2014 Jun 9;56(1444):45 |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
the last Medical Letter article on this subject, consensus guidelines have been published.1 ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
, and pain. Early use of disease-modifying therapy has improved clinical outcomes.1,2 PARENTERAL DRUGS ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

In Brief: FDA Warning on Dronedarone (Multaq)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2011  (Issue 1359)
) approved in 2009 for treatment of atrial fibrillation,1,2 has been associated with “several” cases ...
The FDA and the manufacturer (Sanofi-Aventis) have warned healthcare professionals that use of dronedarone (Multaq), an analog of amiodarone (Cordarone, and others) approved in 2009 for treatment of atrial fibrillation,1,2 has been associated with "several" cases of severe liver injury and hepatic failure, including two that required liver transplants. Both transplants were in women about 70 years old; one had taken the drug for 4.5 months and the other for 6 months. According to the FDA, 147,000 patients have taken dronedarone.3 A new warning in the package insert recommends monitoring...
Med Lett Drugs Ther. 2011 Mar 7;53(1359):17 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
in 2020 and 2021.1,2 STANDARD TREATMENT — Patients with acute VTE have traditionally been treated ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
. An increase in serum aminotransferase levels to >3 times the upper limit of normal (ULN) occurs in 1-2 ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Propofol

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990  (Issue 813)
) and midazolam (Versed). PHARMACOLOGY — Propofol is 2,6-diisopropylphenol formulated as a 1% emulsion ...
Propofol (Diprivan - Stuart), a new intravenous (IV) sedative-hypnotic, was recently marketed in the USA for induction of anesthesia, or for maintenance of general anesthesia as part of a balanced anesthesia regimen. Older drugs used in a similar way include thiopental (Pentothal; and others) and midazolam (Versed).
Med Lett Drugs Ther. 1990 Mar 9;32(813):22 |  Show IntroductionHide Introduction